纳米载体特异性靶向TAMs治疗肿瘤的研究进展

doi:10.12092/j.issn.1009-2501.2018.07.018

中国临床药理学与治疗学 ›› 2018, Vol. 23 ›› Issue (7): 830-835.doi: 10.12092/j.issn.1009-2501.2018.07.018

纳米载体特异性靶向TAMs治疗肿瘤的研究进展

赵小彬^1,2，余陈欢¹，夏爱晓³，俞文英¹，俞冰⁴

¹ 浙江省医学科学院，杭州 310013，浙江；² 嘉兴学院，嘉兴 314001，浙江；³浙江省台州医院，台州 317000，浙江；⁴浙江中医药大学，杭州 310053，浙江

收稿日期:2018-03-22 修回日期:2018-04-28 出版日期:2018-07-26 发布日期:2018-07-20
通讯作者: 俞文英，女，硕士，副研究员，研究方向:抗肿瘤药物靶向载体系统。 Tel：0571-88215628 E-mail:zjyuwenying@163.com
作者简介:赵小彬，女，本科，研究方向:抗肿瘤药物纳米靶向给药系统。 Tel：0571-88215628 E-mail:1392136069@qq.com
基金资助:
浙江省“实验动物基因工程学”创新学科建设（201604）；台州市科技计划项目（1702KY08）；浙江省科技计划项目（2015C33185）

Recent advances of nanocarriers targeting tumor-associated macrophages in tumor therapy

ZHAO Xiaobin ^1,2, YU Chenhuan ¹, XIA Aixiao³, YU Wenying¹, YU Bing ⁴

¹Zhejiang Academy of Medical Sciences, Hangzhou 310013, Zhejiang, China; ²Jiaxing University, Jiaxing 314001, Zhejiang, China;³ Taizhou Hospital of Zhejiang Province, Taizhou 317000, Zhejiang, China; ⁴Zhejiang Chinese Medical University, Hangzhou 310053, Zhejiang, China

Received:2018-03-22 Revised:2018-04-28 Online:2018-07-26 Published:2018-07-20

摘要/Abstract

摘要：

众所周知，肿瘤相关巨噬细胞（tumor-associated macrophages, TAMs）在多种肿瘤的发生、发展及转移过程中扮演着重要角色。越来越多的证据表明，TAMs有可能成为肿瘤治疗的潜在靶点，在未来的肿瘤治疗中发挥重要作用。因此，针对TAMs表面特异表达的受体，设计主动靶向纳米载体，实现抗肿瘤药物在瘤内的合理分布及有效抑瘤已成为目前关注的热点。本文阐述了纳米载体靶向TAMs的优势，并从TAMs特异性高表达受体（甘露糖受体、叶酸受体、分化抗原簇163、分化抗原簇11b等）的角度，对纳米载体表面修饰提高抗肿瘤药物靶向TAMs的能力及抑瘤效果作一综述。

关键词: 肿瘤相关巨噬细胞, 纳米载体, 靶向修饰, 肿瘤治疗

Abstract:

It is well known that tumor-associated macrophages (TAMs) play a vital role in the occurrence, development and metastasis of many tumors. Increasing evidences show that TAMs may be a promising target for tumor therapy and play an important role in future targeted treatment. Therefore, the design of TAMs-targeting nanocarriers which are able to achieve appropriate intratumoral biodistribution so as to effectively inhibit the growth of tumor has become a hot spot in recent years. In this review, the advantages of nanocarriers targeting TAMs are described. Since TAMs display a number of upregulated surface proteins (mannose receptor, folate receptor, cluster of differentiation 163, cluster of differentiation 11b, etc.), specific targeting using targeting ligands coupled to nanocarriers are discussed in the review, which may improve the ability of anti-tumor drug targeting TAMs.

Key words: tumor-associated macrophages, nanocarriers, targeted modification, tumor therapy

中图分类号:

R73
R966

赵小彬，余陈欢，夏爱晓，俞文英，俞冰. 纳米载体特异性靶向TAMs治疗肿瘤的研究进展[J]. 中国临床药理学与治疗学, 2018, 23(7): 830-835.

ZHAO Xiaobin, YU Chenhuan, XIA Aixiao, YU Wenying, YU Bing. Recent advances of nanocarriers targeting tumor-associated macrophages in tumor therapy[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(7): 830-835.

参考文献

［1］Jackute J,Zemaitis M,Pranys D,et al.Distribution of M1 and M2 macrophages in tumor islets and stroma in relation to prognosis of non-small cell lung cancer［J］. BMC Immunol, 2018, 19(1): 3.

［2］Yang L,Zhang Y.Tumor-associated macrophages: from basic research to clinical application［J］. J Hematol Oncol, 2017, 10(1) : 58.

［3］Erdogan S, Torchilin VP. Gadolinium-loaded polychelating polymer-containing tumor- targeted liposomes［J］. Method Mol Biol, 2017, 1522: 179-192.

［4］Fan Y, Yuan S, Huo M, et al. Spatial controlled multistage nanocarriers through hybridization of dendrimers and gelatin nanoparticles for deep penetration and therapy into tumor tissue［J］. Nanomedicine, 2017, 13(4): 1399-1410.

［5］陈芳君, 王增, 蔡鑫君, 等. 靶向肿瘤新生血管唑来膦酸阳离子隐形脂质体抗肿瘤作用的研究［J］. 中国临床药理学与治疗学, 2017, 22(1): 33-36.

［6］Huang L, Chaurasiya B, Wu D, et al. Versatile redox-sensitive pullulan nanoparticles for enhanced liver targeting and efficient cancer therapy［J］. Nanomedicine, 2018, 14(3): 1005-1017.

［7］Li S, Feng S, Ding L, et al. Nanomedicine engulfed by macrophages for targeted tumor therapy［J］. Int J Nanomed, 2016, 11: 4107-4124.

［8］Sosale NG, Spinler KR, Alvey C, et al. Macrophage engulfment of a cell or nanoparticle is regulated by unavoidable opsonization, a species-specific 'Marker of Self' CD47, and target physical properties［J］. Curr Opin Immunol, 2015, 35: 107-112.

［9］Chen L, Simpson JD, Fuchs AV, et al. Effects of surface charge of hyperbranched polymers on cytotoxicity, dynamic cellular uptake and localization, hemotoxicity, and pharmacokinetics in mice［J］. Mol Pharm,2017, 14(12): 4485-4497.

［10］Singh PK, Jaiswal AK, Pawar VK, et al. Fabrication of 3-O-sn-Phosphatidyl-L-serine Anchored PLGA nanoparticle bearing amphotericin B for macrophage targeting［J］. Pharm Res, 2018, 35(3): 60.

［11］Song M, Liu T, Shi C, et al. Bioconjugated manganese dioxide nanoparticles enhance chemotherapy response by priming tumor-associated macrophages toward M1-like phenotype and attenuating tumor hypoxia［J］. Acs Nano, 2016, 10 (3): 633-647.

［12］Peng H, Chen B, Huang W, et al. Reprogramming tumor-associated macrophages to reverse EGFR(T790M) resistance by dual-targeting codelivery of gefitinib/vorinostat［J］. Nano Lett, 2017, 17(12): 7684-7690.

［13］Blykers A, Schoonooghe S, Xavier C, et al. PET imaging of macrophage mannose receptor-expressing macrophages in tumor stroma using 18F-radiolabeled camelid single-domain antibody fragments［J］. J Nucl Med, 2015, 56(8): 1265.

［14］Zhan X, Jia L, Niu Y, et al. Targeted deleption of tumour associated macrophages by an alendronate-glucomannan conjugate for cancer immunotherapy［J］. Biomaterials, 2014, 35(38): 10046-10057.

［15］Zhao PF, Wang YH, Kang XJ, et al. Dual-targeting biomimetic delivery for antiglioma via remodeling tumor microenvironment and directing macrophage-mediated immunotherapy［J］. Chem Sci, 2018, 9: 2674-2689.

［16］Niu M,Valdes S,Naguib YW,et al.Tumor-associated macrophage-mediated targeted therapy of triple-negative breast cancer［J］.Mol Pharm,2016,13(6):1833-1842.

［17］Zeng Z, Dai S, Jiao Y, et al. Mannosylated protamine as a novel DNA vaccine carrier for effective induction of anti-tumor immune responses［J］. Int J Pharm, 2016, 506(1/2): 394-406.

［18］Locke LW, Mayo MW, Yoo AD, et al. PET imaging of tumor associated macrophages using mannose coated 64Cu liposomes［J］. Biomaterials, 2012, 33(31): 7785-7793.

［19］Zhu S, Niu M, O'Mary H, et al. Targeting of tumor-associated macrophages made possible by PEG-sheddable, mannose-modified nanoparticles［J］. Mol Pharm, 2013, 10(9): 3525-3530.

［20］Niu M, Naguib YW, Aldayel AM, et al. Biodistribution and in vivo activities of tumor-associated macrophage-targeting nanoparticles incorporated with doxorubicin［J］. Mol Pharm, 2014, 11(12): 4425-4436.

［21］Turk MJ,Waters DJ,Low PS.Folate-conjugated liposomes preferentially target macrophages associated with ovarian carcinoma［J］.Cancer Lett,2004,213(2):165-172.

［22］Poh S, Chelvam V, Ayala-López W, et al. Selective liposome targeting of folate receptor positive immune cells in inflammatory diseases ［J］. Nanomedicine, 2018, 14(3): 1033-1043.

［23］Penn CA,Yang K,Zong H,et al.Therapeutic impact of nanoparticle therapy targeting tumor-associated macrophages［J］.Mol Cancer Ther,2018,17(1):96-106.

［24］Liu Q,Xu N, Liu L,et al.Dacarbazine-loaded hollow mesoporous silica nanoparticles grafted with folic acid for enhancing anti-metastatic melanoma response［J］.ACS Appl Mater Interfaces,2017,9(26):21673-21687.

［25］Lisi L, Ciotti GM, Braun D, et al. Expression of iNOS, CD163 and ARG1 taken as M1 and M2 markers of micro glial polarization in human gliobla stoma and the surround in gnormal parenchyma［J］. Neurosci Lett, 2017, 645: 106-112.

［26］Zhang WJ, Wang XH, Gao ST, et al. Tumor-associated macrophages correlate with phenomenon of epithelial-mesenchymal transition and contribute to poor prognosis in triple-negative breast cancer patients［J］. J Surg Res, 2018, 222: 93-101.

［27］Ding D,Yao Y,Yang C,et al.Identification of mannose receptor and CD163 as novel biomarkers for colorectal cancer［J］.Cancer Biomark,2018,21(3):689-700.

［28］Kostine M, Briaire-de Bruijn IH, Cleven AHG, et al. Increased infiltration of M2-macrophages, T-cells and PD-L1 expression in high grade leiomyosarcomas supports immunotherapeutic strategies［J］. OncoImmunol, 2017, 7 (2): e1386828.

［29］Etzerodt A,Maniecki MB,Graversen JH,et al.Efficient intracellular drug-targeting of macrophages using stealth liposomes directed to the hemoglobin scavenger receptor CD163［J］.J Control Release,2012,160:72-80.

［30］Zhang QQ, Hu XW, Liu YL, et al. CD11b deficiency suppresses intestinal tumor growth by reducing myeloid cell recruitment［J］. Sci Rep, 2015, 3(5): 15948.

［31］Zhang QF, Yin WW, Xia Y, et al. Liver-infiltrating CD11b-CD27-NK subsets account for NK-cell dysfunction in patients with hepatocellular carcinoma and are associated with tumor progression［J］. Cell Mol Immunol, 2017, 14 (10): 819-829.

［32］Fang J, Ying H, Mao T, et al. Upregulation of CD11b and CD86 through LSD1 inhibition promotes myeloid differentiation and suppresses cell proliferation in human monocytic leukemia cells［J］. Nat Rev Cancer, 2017, 8: 85085-85101.

［33］Zhang M,Kim JA.Effect of molecular size and modification pattern on the internalization of water soluble β-(1→3)-(1→4)-glucan by primary murine macrophages［J］.Int J Biochem Cell Biol,2012,44(6):914-927.

［34］Zhang M,Gao Y,Caja K,et al.Non-viral nanoparticle delivers small interfering RNA to macrophages in vitro and in vivo［J］.PLoS One,2015,10:e0118472.

［35］Edgington-Mitchell LE, Wartmann T, Fleming AK, et al. Legumain is activated in macrophages during pancreatitis［J］. Am J Physiol Gastrointest Liver Physiol, 2016, 311(3): 548-560.

［36］Mai CW, Chung FF,Leong CO. Targeting legumain as a novel therapeutic strategy in cancers［J］. Curr Drug Targets, 2017, 18(11): 1259-1268.

［37］Li N, Liu Q, Su Q, et al. Effects of legumain as a potential prognostic factor on gastric cancers ［J］. Med Oncol, 2013, 30(3): 621.

［38］申龙,康立春,王德坤,等.肿瘤相关巨噬细胞中敲除Legumain可以通过促进肿瘤衰老来抑制肿瘤发展［C］.第十二届全国免疫学学术大会摘要汇编,2017.

［39］Shen L,Li H,Shi Y,et al.M2 tumour-associated macrophages contribute to tumour progression via legumain remodelling the extracellular matrix in diffuse large B cell lymphoma［J］.Sci Rep,2016,6:30347.

［40］Liu Z,Xiong M,Gong J,et al.Legumain protease-activated TAT-liposome cargo for targeting tumours and their microenvironment［J］.Nat Commun,2014,5:4280.

［41］Zhang X, Tian W, Cai X, et al. Hydrazinocurcumin encapsuled nanoparticles "re-educate" tumor-associated macrophages and exhibitAnti-tumor effects on breast cancer following STAT3 suppression［J］. PLoS One, 2013, 8(6): e65896.

［42］Liu M, Luo F, Ding C, et al. Dectin-1 activation by a natural product β-glucan converts immunosuppressive macrophages into an M1-like phenotype［J］. J Immunol, 2015, 195(10): 5055-5065.

［43］Ngambenjawong C, Pun SH. Multivalent polymers displaying M2 macrophage-targeting peptides improve target binding avidity and serum stability［J］. ACS Biomater Sci Eng, 2017, 3(9): 2050-2053.

［44］Zhou S, Zhang T, Peng B, et al. Targeted delivery of epirubicin to tumor-associated macrophages by sialic acid-cholesterol conjugate modified liposomes with improved antitumor activity［J］. Int J Pharm, 2017, 523(1): 203-216.

［45］Qian Y, Qiao S, Dai Y, et al. Molecular-targeted immunotherapeutic strategy for melanoma via dual-targeting nanoparticles delivering small interfering RNA to tumor-associated macrophages ［J］. ACS Nano, 2017, 11(9): 9536-9549.

[1]	赵文超, 邱艳芳, 谭嵘. 肿瘤治疗中靶向DNA损伤反应[J]. 中国临床药理学与治疗学, 2020, 25(8): 943-952.
[2]	张锴婷，陈乃涵. 生物药在肿瘤治疗领域的临床研究进展[J]. 中国临床药理学与治疗学, 2020, 25(1): 32-43.
[3]	许丽华，徐肖阳，徐骏军，俞文英. 表面修饰白蛋白纳米粒在肿瘤靶向治疗中的研究进展[J]. 中国临床药理学与治疗学, 2017, 22(8): 948-954.
[4]	陈星，吴为玲，陈姗姗，叶丽娅，梅双双，王静，何钰，柴泽英. 基于肿瘤相关巨噬细胞的宫颈癌免疫学病理机制研究[J]. 中国临床药理学与治疗学, 2017, 22(12): 1394-1399.
[5]	艾雄飞，杜丹玉，孙立，林森森，袁胜涛. 靶向肿瘤相关巨噬细胞的治疗进展及风险[J]. 中国临床药理学与治疗学, 2016, 21(6): 697-702.
[6]	张雪, 吴兰香, 张陶蓝, 温纯洁, 付利娟, 周宏灏. β-异硫氰酸苯乙酯多靶向抗肿瘤作用机制研究进展[J]. 中国临床药理学与治疗学, 2015, 20(2): 217-222.
[7]	马爱妞, 王永祥, 周向军. 靶向诱导DNA 甲基化与肿瘤治疗研究进展[J]. 中国临床药理学与治疗学, 2009, 14(3): 241-244.
[8]	卢丽娜, 杨婷, 庄则豪. 环氧合酶及其抑制剂与肿瘤防治的研究进展[J]. 中国临床药理学与治疗学, 2006, 11(1): 22-26.
[9]	李哲, 袁守军. 表皮生长因子受体酪氨酸激酶抑制剂在肿瘤治疗中的应用[J]. 中国临床药理学与治疗学, 2004, 9(4): 361-364.

纳米载体特异性靶向TAMs治疗肿瘤的研究进展

Recent advances of nanocarriers targeting tumor-associated macrophages in tumor therapy

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 9

编辑推荐

Metrics

本文评价